The estimated Net Worth of Steven C Jones is at least $66.1 million dollars as of 7 January 2021. Mr. Jones owns over 117,286 units of Neogenomics stock worth over $1,471,456 and over the last 9 years he sold NEO stock worth over $64,382,950. In addition, he makes $272,697 as Director at Neogenomics.
Sign up
Mr. Jones NEO stock SEC Form 4 insiders trading
Steven has made over 21 trades of the Neogenomics stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 117,286 units of NEO stock worth $918,349 on 7 January 2021.
The largest trade he's ever made was selling 299,873 units of Neogenomics stock on 26 February 2019 worth over $5,667,600. On average, Steven trades about 116,635 units every 62 days since 2016. As of 7 January 2021 he still owns at least 90,218 units of Neogenomics stock.
You can see the complete history of Mr. Jones stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Jones biography
Steven C. Jones serves as Director of the Company. Mr. Jones has served as a director since October 2003. He also served in various executive roles from 2003 – 2019. He served as the Company’s Executive Vice President from 2016 until 2019, Executive Vice President - Finance from 2009 until 2016 and as Chief Compliance Officer from 2013 until 2018. Mr. Jones also served as Chief Financial Officer for the Company from October 2003 until November 30, 2009. Mr. Jones is the founder of Aspen Capital Group, a private equity investment firm, and has served as its Managing Partner since 2005. Prior to that, Mr. Jones was a chief financial officer at various public and private companies and was a Vice President in the Investment Banking Group at Merrill Lynch & Co. Mr. Jones received his B.S. degree in Computer Engineering from the University of Michigan in 1985 and his MBA degree from the Wharton School of the University of Pennsylvania in 1991. He also serves on the Boards of Directors of ERP Maestro, Inc., a Software as a Service provider of cybersecurity access management solutions, and XG Sciences, Inc., an advanced materials company that publicly files reports with the SEC. Mr. Jones serves on the Audit and Compensation Committees of ERP Maestro, and on the Audit, Compensation and Executive Committees of XG Sciences.
What is the salary of Steven Jones?
As the Director of Neogenomics, the total compensation of Steven Jones at Neogenomics is $272,697. There are 8 executives at Neogenomics getting paid more, with Douglas VanOort having the highest compensation of $3,648,730.
How old is Steven Jones?
Steven Jones is 56, he's been the Director of Neogenomics since 2019. There are 14 older and 11 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
What's Steven Jones's mailing address?
Steven's mailing address filed with the SEC is 12701 COMMONWEALTH DRIVE SUITE 9, , FORT MYERS, FL, 33913.
Insiders trading at Neogenomics
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van et Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
What does Neogenomics do?
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
What does Neogenomics's logo look like?
Complete history of Mr. Jones stock trades at Neogenomics
Neogenomics executives and stock owners
Neogenomics executives and other stock owners filed with the SEC include:
-
Douglas VanOort,
Chairman of the Board, Chief Executive Officer -
Robert Shovlin,
President - Clinical Services Division -
Lawrence Weiss,
Chief Medical Officer -
George Cardoza,
President - Pharma Services Division -
William Bonello,
President, Informatics and Director of Investor Relations -
Douglas M. Brown,
Chief Strategy & Corp. Devel. Officer -
Kathryn McKenzie,
Chief Financial Officer -
Steven Ross,
Chief Information Officer -
Steven Jones,
Director -
Alison Hannah,
Independent Director -
Lynn Tetrault,
Lead Independent Director -
Raymond Hipp,
Independent Director -
Bruce Crowther,
Independent Director -
Kevin Johnson,
Independent Director -
Stephen Kanovsky,
Independent Director -
Michael Kelly,
Independent Director -
Rachel Stahler,
Director -
Douglas Brown,
Chief Strategy and Corporate Development Officer -
Denise Pedulla,
General Counsel, Corporate Secretary -
Jennifer Balliet,
Vice President, Chief Culture Officer -
Stephanie Bywater,
Chief Compliance Officer -
Cynthia Dieter,
Chief Accounting Officer, Controller -
Dr. Steven G. Brodie FACMG, Ph.D.,
Sr. VP of Laboratory Operations -
George A. Cardoza,
Pres & COO of Lab Operations -
Marcus B. Silva J.D., M.B.A.,
Chief Marketing Officer -
Halley E. Gilbert Esq., J.D.,
Chief Legal Officer -
Charlie Eidson,
Director of Investor Relations and Corp. Devel. -
John Mooney,
Chief Technology Officer -
Cynthia J. Dieter,
Chief Accounting Officer & Controller -
Mark W. Mallon,
CEO & Director -
William J Robison,
Director -
Maher Albitar,
Chief Medical Officer -
Sharon Virag,
Chief Financial Officer -
David Sholehvar,
President, Clinical Services -
Neil Gunn,
Director -
Elizabeth Floegel,
Director -
Anthony P. Zook,
Director -
Christopher M Smith,
Chief Executive Officer -
Mark Alan Machulcz,
Vice President of Operations -
Michael T Dent,
Director -
Steven G. Brodie,
Chief Scientific Officer -
Steven Caspen Select Health...,
Executive VP of FinanceExecutive VP of Finance -
Robert H. Horel,
Vice President andGM PathLogic -
Robert P Gasparini,
Chief Science Officer -
Halley E Gilbert,
Chief Legal Officer -
Gina M Wallar,
President, Pharma Services -
Mark Mallon,
Chief Executive Officer -
Clive Morris,
President of Inivata -
Oort Douglas M Van,
Director -
David Daly,
Director -
Vishal Sikri,
President Advanced Diagnostics -
David Brian Perez,
Director -
Jeffrey Scott Sherman,
Chief Financial Officer -
Shashikant Kulkarni,
Chief Scientific Officer -
Alicia C Olivo,
General Counsel -
Melody Harris,
Chf Ops Off, Pres, Informatics -
Greg D Aunan,
Chief Accounting Officer -
Warren Stone,
Chief Commerical Officer